Clinical characteristics, disease activity, functional status, and quality of life results of patients with psoriatic arthritis using biological and conventional synthetic disease-modifying antirheumatic drugs

Öz:

Objectives: This study aims to compare the clinical characteristics, disease activity, and quality of life (QoL) of patients with psoriatic arthritis (PsA) who use biological and conventional synthetic disease-modifying antirheumatic drugs (DMARDs) in a nationwide cohort throughout Turkey. Patients and methods: A total of 961 patients (346 males, 615 females; mean age: 46.9±12.2 years; range, 18 to 81 years) with PsA according to the classification criteria for PsA were included in the study. The patients’ demographic and clinical characteristics, physical examination results, Disease Activity Score 28, Disease Activity Index for Psoriatic Arthritis and Bath Ankylosing Spondylitis Disease Activity Index (BASDAI), Psoriasis Area and Severity Index, Bath Ankylosing Spondylitis Functional Index, Bath Ankylosing Spondylitis Metrology Index, Hospital Anxiety and Depression Scale, Health Assessment Questionnaire, Psoriatic Arthritis Quality of Life (PsAQoL), and Short Form-36 scores were all recorded. Results: Of the patients, 23% underwent biological DMARD (bDMARD) monotherapy, 42% underwent conventional synthetic DMARD (csDMARD) monotherapy, 10% underwent a csDMARD combination therapy, and 10% underwent a combination bDMARD and csDMARD treatment. The Visual Analog Scale (VAS pain), patient global assessment, physician global assessment, and BASDAI scores were found to be lower among patients using combination treatment of csDMARD and bDMARD, while the swollen joint count was found to be lower among patients using bDMARD. The PsAQoL score was found to be the lowest among patients not using any medication and the highest among those using bDMARD. Conclusion: In our study, patients with PsA were successfully treated with both csDMARD and bDMARD monotherapy. When the biological treatments used for PsA were compared with csDMARD, it was found that biological treatments had a positive effect on both disease activity and the QoL. Combinations of csDMARDs and bDMARDs were preferred in cases in which the disease activity was still high or increased. Because of the highest efficacy of the combined treatment, we highly suggest increasing the number of patients on combined treatment.

Anahtar Kelime:

Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık

1. Kruithof E, Baeten D, De Rycke L, Vandooren B, Foell D, Roth J, et al. Synovial histopathology of psoriatic arthritis, both oligo- and polyarticular, resembles spondyloarthropathy more than it does rheumatoid arthritis. Arthritis Res Ther 2005;7:R569-80.
2. Mease PJ, Gladman DD, Papp KA, Khraishi MM, Thaçi D, Behrens F, et al. Prevalence of rheumatologistdiagnosed psoriatic arthritis in patients with psoriasis in European/North American dermatology clinics. J Am Acad Dermatol 2013;69:729-35.
3. Boehncke WH, Menter A. Burden of disease: psoriasis and psoriatic arthritis. Am J Clin Dermatol 2013;14:377- 88.
4. Strand V, Sharp V, Koenig AS, Park G, Shi Y, Wang B, et al. Comparison of health-related quality of life in rheumatoid arthritis, psoriatic arthritis and psoriasis and effects of etanercept treatment. Ann Rheum Dis 2012;71:1143-50.
5. Husted JA, Tom BD, Farewell VT, Schentag CT, Gladman DD. Description and prediction of physical functional disability in psoriatic arthritis: a longitudinal analysis using a Markov model approach. Arthritis Rheum 2005;53:404-9.
6. Minnock P, Kirwan J, Veale D, Fitzgerald O, Bresnihan B. Fatigue is an independent outcome measure and is sensitive to change in patients with psoriatic arthritis. Clin Exp Rheumatol 2010;28:401-4.
7. Ogdie A, Schwartzman S, Eder L, Maharaj AB, Zisman D, Raychaudhuri SP, et al. Comprehensive treatment of psoriatic arthritis: managing comorbidities and extraarticular manifestations. J Rheumatol 2014;41:2315-22.
8. McLaughlin M, Ostör A. Early treatment of psoriatic arthritis improves prognosis. Practitioner 2014;258:21-4, 3.
9. Gossec L, Smolen JS, Ramiro S, de Wit M, Cutolo M, Dougados M, et al. European League Against Rheumatism (EULAR) recommendations for the management of psoriatic arthritis with pharmacological therapies: 2015 update. Ann Rheum Dis 2016;75:499-510.
10. Braun J, van den Berg R, Baraliakos X, Boehm H, Burgos-Vargas R, Collantes-Estevez E, et al. 2010 update of the ASAS/EULAR recommendations for the management of ankylosing spondylitis. Ann Rheum Dis 2011;70:896-904.
11. Coates LC, Gossec L, Ramiro S, Mease P, van der Heijde D, Smolen JS, et al. New GRAPPA and EULAR recommendations for the management of psoriatic arthritis. Rheumatology 2017;56:1251-3.
12. Garrett S, Jenkinson T, Kennedy LG, Whitelock H, Gaisford P, Calin A. A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index. J Rheumatol 1994;21:2286-91.
13. Schoels MM, Aletaha D, Alasti F, Smolen JS. Disease activity in psoriatic arthritis (PsA): defining remission and treatment success using the DAPSA score. Ann Rheum Dis 2016;75:811-8.
14. Feldman SR, Fleischer AB Jr, Reboussin DM, Rapp SR, Exum ML, Clark AR, et al. The self-administered psoriasis area and severity index is valid and reliable. J Invest Dermatol 1996;106:183-6.
15. Calin A, Garrett S, Whitelock H, Kennedy LG, O'Hea J, Mallorie P, et al. A new approach to defining functional ability in ankylosing spondylitis: the development of the Bath Ankylosing Spondylitis Functional Index. J Rheumatol 1994;21:2281-5.
16. Jenkinson TR, Mallorie PA, Whitelock HC, Kennedy LG, Garrett SL, Calin A. Defining spinal mobility in ankylosing spondylitis (AS). The Bath AS Metrology Index. J Rheumatol 1994;21:1694-8.
17. Bruce B, Fries JF. The Health Assessment Questionnaire (HAQ). Clin Exp Rheumatol 2005;23:S14-8.
18. McKenna SP, Doward LC, Whalley D, Tennant A, Emery P, Veale DJ. Development of the PsAQoL: a quality of life instrument specific to psoriatic arthritis. Ann Rheum Dis 2004;63:162-9.
19. Leung YY, Ho KW, Zhu TY, Tam LS, Kun EW, Li EK. Testing scaling assumptions, reliability and validity of medical outcomes study short-form 36 health survey in psoriatic arthritis. Rheumatology 2010;49:1495-501.
20. Saad AA, Ashcroft DM, Watson KD, Symmons DP, Noyce PR, Hyrich KL, et al. Improvements in quality of life and functional status in patients with psoriatic arthritis receiving anti-tumor necrosis factor therapies. Arthritis Care Res 2010;62:345-53.
21. Tymms K, Kelly A, Bird P, Griffiths H, de Jager J, Littlejohn G, et al. Psoriatic arthritis treatment regimens, therapy duration and reasons for cessation in the biologics era: a multi-centre Australian study. Int J Rheum Dis 2018;21:510-6.
22. Polachek A, Al-Johani R, Li S, Ye JY, Chandran V, Gladman D. Late onset psoriatic arthritis in a longitudinal cohort: Disease presentation, activity over time and prognosis. Semin Arthritis Rheum 2019;48:834-9.
23. Sørensen J, Hetland ML. Diagnostic delay in patients with rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis: results from the Danish nationwide DANBIO registry. Ann Rheum Dis 2015;74:e12.
24. Aletaha D, Alasti F, Smolen JS. Disease activity states of the DAPSA, a psoriatic arthritis specific instrument, are valid against functional status and structural progression. Ann Rheum Dis 2017;76:418-21.
25. Lubrano E, De Socio A, Perrotta FM. Comparison of Composite Indices Tailored for Psoriatic Arthritis Treated with csDMARD and bDMARD: A Crosssectional Analysis of a Longitudinal Cohort. J Rheumatol 2017;44:1159-64.
26. Mease PJ, Accortt NA, Rebello S, Etzel CJ, Harrison RW, Aras GA, et al. Persistence of tumor necrosis factor inhibitor or conventional synthetic disease-modifying antirheumatic drug monotherapy or combination therapy in psoriatic arthritis in a real-world setting. Rheumatol Int 2019;39:1547-58.
27. Lu C, Wallace BI, Waljee AK, Fu W, Zhang Q, Liu Y. Comparative efficacy and safety of targeted DMARDs for active psoriatic arthritis during induction therapy: A systematic review and network meta-analysis. Semin Arthritis Rheum 2019;49:381-8.
28. Tan AL, McGonagle D. Psoriatic arthritis: correlation between imaging and pathology. Joint Bone Spine 2010;77:206-11.
29. Polachek A, Li S, Chandran V, Gladman DD. Clinical Enthesitis in a Prospective Longitudinal Psoriatic Arthritis Cohort: Incidence, Prevalence, Characteristics, and Outcome. Arthritis Care Res 2017;69:1685-91.
30. Pontifex EK, Dissanayake K, Bursill D, Gill T. Prevalence of minimal disease activity in Australian patients with Psoriatic Arthritis: Assessing the outcome of national funding criteria for biologic disease-modifying antirheumatic drug prescribing. Int J Rheum Dis 2019;22:262-8.
31. Sakkas LI, Alexiou I, Simopoulou T, Vlychou M. Enthesitis in psoriatic arthritis. Semin Arthritis Rheum 2013;43:325-34.
32. Coates LC, Kavanaugh A, Mease PJ, Soriano ER, Laura Acosta-Felquer M, Armstrong AW, et al. Group for Research and Assessment of Psoriasis and Psoriatic Arthritis 2015 Treatment Recommendations for Psoriatic Arthritis. Arthritis Rheumatol 2016;68:1060-71.
33. Dongze W, Wong PC, Griffith JF, Tam L-S. FRI0464 Effect of biologics on enthesitis and dactylitis in patients with psoriatic arthritis: a systematic review and metaanalysis. Ann Rheum Dis 2019;78(Suppl 2):926-7.
34. Silvagni E, Bortoluzzi A, Ciancio G, Govoni M. Biological and synthetic target DMARDs in psoriatic arthritis. Pharmacol Res 2019;149:104473.
35. Tälli S, Etcheto A, Fautrel B, Balanescu A, Braun J, Cañete JD, et al. Patient global assessment in psoriatic arthritis - what does it mean? An analysis of 223 patients from the Psoriatic arthritis impact of disease (PsAID) study. Joint Bone Spine 2016;83:335-40.
36. Queiro R, Cañete JD, Montilla C, Abad M, Montoro M, Gómez S, et al. Minimal disease activity and impact of disease in psoriatic arthritis: a Spanish cross-sectional multicenter study. Arthritis Res Ther 2017;19:72.
37. Fagerli KM, Lie E, van der Heijde D, Heiberg MS, Lexberg AS, Rødevand E, et al. The role of methotrexate co-medication in TNF-inhibitor treatment in patients with psoriatic arthritis: results from 440 patients included in the NOR-DMARD study. Ann Rheum Dis 2014;73:132-7.
38. Lee S, Mendelsohn A, Sarnes E. The burden of psoriatic arthritis: a literature review from a global health systems perspective. P T 2010;35:680-9.
39. Gottlieb A, Gratacos J, Dikranian A, van Tubergen A, Fallon L, Emir B, et al. Treatment patterns, unmet need, and impact on patient-reported outcomes of psoriatic arthritis in the United States and Europe. Rheumatol Int 2019;39:121-30.
40. Heiberg MS, Kaufmann C, Rødevand E, Mikkelsen K, Koldingsnes W, Mowinckel P, et al. The comparative effectiveness of anti-TNF therapy and methotrexate in patients with psoriatic arthritis: 6 month results from a longitudinal, observational, multicentre study. Ann Rheum Dis 2007;66:1038-42.
41. Rosen CF, Mussani F, Chandran V, Eder L, Thavaneswaran A, Gladman DD. Patients with psoriatic arthritis have worse quality of life than those with psoriasis alone. Rheumatology 2012;51:571-6.
42. Ozcan E, Yilmaz O, Tutoglu A, Bodur H. Validity and reliability of the Turkish version of the Health Assessment Questionnaire for the Spondyloarthropathies. Rheumatol Int 2012;32:1563-8.
43. Wohl Y, Reitblat O, Lerman TT, Cohen O, Reitblat T. Psychologic Morbidity Among Psoriatic Arthritis Patients in Remission or With Low Disease Activity: A Comparison Between Biologic and Conventional Synthetic Disease-Modifying Antirheumatic Drugs. J Clin Rheumatol. 2019. [Epub ahead of print]
44. Tillett W, Shaddick G, Jobling A, Askari A, Cooper A, Creamer P, et al. Effect of anti-TNF and conventional synthetic disease-modifying anti-rheumatic drug treatment on work disability and clinical outcome in a multicentre observational cohort study of psoriatic arthritis. Rheumatology 2017;56:603-12.

APA	Keskin Y, NAS K, KILIÇ E, Sargın B, Acer Kasman S, alkan h, Sahin N, cengiz g, cüzdan balta n, Albayrak İ, Keskin D, mülkoğlu c, resorlu h, ataman s, Bal A, Duruöz M, Küçükakkaş o, YURDAKUL O, Alkan Melikoglu M, AYDIN Y, Ayhan F, Bodur H, Calis M, capkin e, Devrimsel G, Orhan K, hizmetli s, KAMANLI A, Ecesoy H, kutluk ö, Şen N, SENDUR O, TEKEOGLU I, Tolu S, toprak m, tuncer t (2021). Clinical characteristics, disease activity, functional status, and quality of life results of patients with psoriatic arthritis using biological and conventional synthetic disease-modifying antirheumatic drugs. , 1 - 9. 10.46497/ArchRheumatol.2021.7874
Chicago	Keskin Yaşar,NAS Kemal,KILIÇ Erkan,Sargın Betül,Acer Kasman Sevtap,alkan hakan,Sahin Nilay,cengiz gizem,cüzdan balta nihan,Albayrak İlknur,Keskin Dilek,mülkoğlu cevriye,resorlu hatice,ataman sebnem,Bal Ajda,Duruöz Mehmet Tuncay,Küçükakkaş okan,YURDAKUL Ozan Volkan,Alkan Melikoglu Meltem,AYDIN YILDIRAY,Ayhan Fikriye Figen,Bodur Hatice,Calis Mustafa,capkin erhan,Devrimsel Gul,Orhan Kevser,hizmetli sami,KAMANLI Ayhan,Ecesoy Hilal,kutluk öznur,Şen Nesrin,SENDUR OMER FARUK,TEKEOGLU IBRAHIM,Tolu Sena,toprak murat,tuncer tiraje Clinical characteristics, disease activity, functional status, and quality of life results of patients with psoriatic arthritis using biological and conventional synthetic disease-modifying antirheumatic drugs. (2021): 1 - 9. 10.46497/ArchRheumatol.2021.7874
MLA	Keskin Yaşar,NAS Kemal,KILIÇ Erkan,Sargın Betül,Acer Kasman Sevtap,alkan hakan,Sahin Nilay,cengiz gizem,cüzdan balta nihan,Albayrak İlknur,Keskin Dilek,mülkoğlu cevriye,resorlu hatice,ataman sebnem,Bal Ajda,Duruöz Mehmet Tuncay,Küçükakkaş okan,YURDAKUL Ozan Volkan,Alkan Melikoglu Meltem,AYDIN YILDIRAY,Ayhan Fikriye Figen,Bodur Hatice,Calis Mustafa,capkin erhan,Devrimsel Gul,Orhan Kevser,hizmetli sami,KAMANLI Ayhan,Ecesoy Hilal,kutluk öznur,Şen Nesrin,SENDUR OMER FARUK,TEKEOGLU IBRAHIM,Tolu Sena,toprak murat,tuncer tiraje Clinical characteristics, disease activity, functional status, and quality of life results of patients with psoriatic arthritis using biological and conventional synthetic disease-modifying antirheumatic drugs. , 2021, ss.1 - 9. 10.46497/ArchRheumatol.2021.7874
AMA	Keskin Y,NAS K,KILIÇ E,Sargın B,Acer Kasman S,alkan h,Sahin N,cengiz g,cüzdan balta n,Albayrak İ,Keskin D,mülkoğlu c,resorlu h,ataman s,Bal A,Duruöz M,Küçükakkaş o,YURDAKUL O,Alkan Melikoglu M,AYDIN Y,Ayhan F,Bodur H,Calis M,capkin e,Devrimsel G,Orhan K,hizmetli s,KAMANLI A,Ecesoy H,kutluk ö,Şen N,SENDUR O,TEKEOGLU I,Tolu S,toprak m,tuncer t Clinical characteristics, disease activity, functional status, and quality of life results of patients with psoriatic arthritis using biological and conventional synthetic disease-modifying antirheumatic drugs. . 2021; 1 - 9. 10.46497/ArchRheumatol.2021.7874
Vancouver	Keskin Y,NAS K,KILIÇ E,Sargın B,Acer Kasman S,alkan h,Sahin N,cengiz g,cüzdan balta n,Albayrak İ,Keskin D,mülkoğlu c,resorlu h,ataman s,Bal A,Duruöz M,Küçükakkaş o,YURDAKUL O,Alkan Melikoglu M,AYDIN Y,Ayhan F,Bodur H,Calis M,capkin e,Devrimsel G,Orhan K,hizmetli s,KAMANLI A,Ecesoy H,kutluk ö,Şen N,SENDUR O,TEKEOGLU I,Tolu S,toprak m,tuncer t Clinical characteristics, disease activity, functional status, and quality of life results of patients with psoriatic arthritis using biological and conventional synthetic disease-modifying antirheumatic drugs. . 2021; 1 - 9. 10.46497/ArchRheumatol.2021.7874
IEEE	Keskin Y,NAS K,KILIÇ E,Sargın B,Acer Kasman S,alkan h,Sahin N,cengiz g,cüzdan balta n,Albayrak İ,Keskin D,mülkoğlu c,resorlu h,ataman s,Bal A,Duruöz M,Küçükakkaş o,YURDAKUL O,Alkan Melikoglu M,AYDIN Y,Ayhan F,Bodur H,Calis M,capkin e,Devrimsel G,Orhan K,hizmetli s,KAMANLI A,Ecesoy H,kutluk ö,Şen N,SENDUR O,TEKEOGLU I,Tolu S,toprak m,tuncer t "Clinical characteristics, disease activity, functional status, and quality of life results of patients with psoriatic arthritis using biological and conventional synthetic disease-modifying antirheumatic drugs." , ss.1 - 9, 2021. 10.46497/ArchRheumatol.2021.7874
ISNAD	Keskin, Yaşar vd. "Clinical characteristics, disease activity, functional status, and quality of life results of patients with psoriatic arthritis using biological and conventional synthetic disease-modifying antirheumatic drugs". (2021), 1-9. https://doi.org/10.46497/ArchRheumatol.2021.7874

APA	Keskin Y, NAS K, KILIÇ E, Sargın B, Acer Kasman S, alkan h, Sahin N, cengiz g, cüzdan balta n, Albayrak İ, Keskin D, mülkoğlu c, resorlu h, ataman s, Bal A, Duruöz M, Küçükakkaş o, YURDAKUL O, Alkan Melikoglu M, AYDIN Y, Ayhan F, Bodur H, Calis M, capkin e, Devrimsel G, Orhan K, hizmetli s, KAMANLI A, Ecesoy H, kutluk ö, Şen N, SENDUR O, TEKEOGLU I, Tolu S, toprak m, tuncer t (2021). Clinical characteristics, disease activity, functional status, and quality of life results of patients with psoriatic arthritis using biological and conventional synthetic disease-modifying antirheumatic drugs. Archives of Rheumatology, 36(1), 1 - 9. 10.46497/ArchRheumatol.2021.7874
Chicago	Keskin Yaşar,NAS Kemal,KILIÇ Erkan,Sargın Betül,Acer Kasman Sevtap,alkan hakan,Sahin Nilay,cengiz gizem,cüzdan balta nihan,Albayrak İlknur,Keskin Dilek,mülkoğlu cevriye,resorlu hatice,ataman sebnem,Bal Ajda,Duruöz Mehmet Tuncay,Küçükakkaş okan,YURDAKUL Ozan Volkan,Alkan Melikoglu Meltem,AYDIN YILDIRAY,Ayhan Fikriye Figen,Bodur Hatice,Calis Mustafa,capkin erhan,Devrimsel Gul,Orhan Kevser,hizmetli sami,KAMANLI Ayhan,Ecesoy Hilal,kutluk öznur,Şen Nesrin,SENDUR OMER FARUK,TEKEOGLU IBRAHIM,Tolu Sena,toprak murat,tuncer tiraje Clinical characteristics, disease activity, functional status, and quality of life results of patients with psoriatic arthritis using biological and conventional synthetic disease-modifying antirheumatic drugs. Archives of Rheumatology 36, no.1 (2021): 1 - 9. 10.46497/ArchRheumatol.2021.7874
MLA	Keskin Yaşar,NAS Kemal,KILIÇ Erkan,Sargın Betül,Acer Kasman Sevtap,alkan hakan,Sahin Nilay,cengiz gizem,cüzdan balta nihan,Albayrak İlknur,Keskin Dilek,mülkoğlu cevriye,resorlu hatice,ataman sebnem,Bal Ajda,Duruöz Mehmet Tuncay,Küçükakkaş okan,YURDAKUL Ozan Volkan,Alkan Melikoglu Meltem,AYDIN YILDIRAY,Ayhan Fikriye Figen,Bodur Hatice,Calis Mustafa,capkin erhan,Devrimsel Gul,Orhan Kevser,hizmetli sami,KAMANLI Ayhan,Ecesoy Hilal,kutluk öznur,Şen Nesrin,SENDUR OMER FARUK,TEKEOGLU IBRAHIM,Tolu Sena,toprak murat,tuncer tiraje Clinical characteristics, disease activity, functional status, and quality of life results of patients with psoriatic arthritis using biological and conventional synthetic disease-modifying antirheumatic drugs. Archives of Rheumatology, vol.36, no.1, 2021, ss.1 - 9. 10.46497/ArchRheumatol.2021.7874
AMA	Keskin Y,NAS K,KILIÇ E,Sargın B,Acer Kasman S,alkan h,Sahin N,cengiz g,cüzdan balta n,Albayrak İ,Keskin D,mülkoğlu c,resorlu h,ataman s,Bal A,Duruöz M,Küçükakkaş o,YURDAKUL O,Alkan Melikoglu M,AYDIN Y,Ayhan F,Bodur H,Calis M,capkin e,Devrimsel G,Orhan K,hizmetli s,KAMANLI A,Ecesoy H,kutluk ö,Şen N,SENDUR O,TEKEOGLU I,Tolu S,toprak m,tuncer t Clinical characteristics, disease activity, functional status, and quality of life results of patients with psoriatic arthritis using biological and conventional synthetic disease-modifying antirheumatic drugs. Archives of Rheumatology. 2021; 36(1): 1 - 9. 10.46497/ArchRheumatol.2021.7874
Vancouver	Keskin Y,NAS K,KILIÇ E,Sargın B,Acer Kasman S,alkan h,Sahin N,cengiz g,cüzdan balta n,Albayrak İ,Keskin D,mülkoğlu c,resorlu h,ataman s,Bal A,Duruöz M,Küçükakkaş o,YURDAKUL O,Alkan Melikoglu M,AYDIN Y,Ayhan F,Bodur H,Calis M,capkin e,Devrimsel G,Orhan K,hizmetli s,KAMANLI A,Ecesoy H,kutluk ö,Şen N,SENDUR O,TEKEOGLU I,Tolu S,toprak m,tuncer t Clinical characteristics, disease activity, functional status, and quality of life results of patients with psoriatic arthritis using biological and conventional synthetic disease-modifying antirheumatic drugs. Archives of Rheumatology. 2021; 36(1): 1 - 9. 10.46497/ArchRheumatol.2021.7874
IEEE	Keskin Y,NAS K,KILIÇ E,Sargın B,Acer Kasman S,alkan h,Sahin N,cengiz g,cüzdan balta n,Albayrak İ,Keskin D,mülkoğlu c,resorlu h,ataman s,Bal A,Duruöz M,Küçükakkaş o,YURDAKUL O,Alkan Melikoglu M,AYDIN Y,Ayhan F,Bodur H,Calis M,capkin e,Devrimsel G,Orhan K,hizmetli s,KAMANLI A,Ecesoy H,kutluk ö,Şen N,SENDUR O,TEKEOGLU I,Tolu S,toprak m,tuncer t "Clinical characteristics, disease activity, functional status, and quality of life results of patients with psoriatic arthritis using biological and conventional synthetic disease-modifying antirheumatic drugs." Archives of Rheumatology, 36, ss.1 - 9, 2021. 10.46497/ArchRheumatol.2021.7874
ISNAD	Keskin, Yaşar vd. "Clinical characteristics, disease activity, functional status, and quality of life results of patients with psoriatic arthritis using biological and conventional synthetic disease-modifying antirheumatic drugs". Archives of Rheumatology 36/1 (2021), 1-9. https://doi.org/10.46497/ArchRheumatol.2021.7874